| # | Title | Journal | Year | Citations |
|---|
| 1 | Targeted agents and immunotherapies: optimizing outcomes in melanoma | Nature Reviews Clinical Oncology | 2017 | 945 |
| 2 | Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma | JAMA Oncology | 2017 | 750 |
| 3 | Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer | JAMA - Journal of the American Medical Association | 2017 | 670 |
| 4 | Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study | Lancet Oncology, The | 2011 | 356 |
| 5 | A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 | Blood | 2019 | 292 |
| 6 | Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study | Clinical Cancer Research | 2020 | 273 |
| 7 | Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503) | Lancet Respiratory Medicine,the | 2018 | 268 |
| 8 | Determinants of telomere length across human tissues | Science | 2020 | 257 |
| 9 | Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome | Journal of Clinical Oncology | 2019 | 234 |
| 10 | Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2 | Nature Immunology | 2011 | 169 |
| 11 | Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience | Blood | 2016 | 166 |
| 12 | Assessing gynecologic and breast cancer survivors' sexual health care needs | Cancer | 2011 | 151 |
| 13 | Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis | JAMA Oncology | 2018 | 147 |
| 14 | RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia | Nature Communications | 2018 | 132 |
| 15 | Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study | Lancet Oncology, The | 2019 | 124 |
| 16 | How I treat acute lymphoblastic leukemia in older adolescents and young adults | Blood | 2015 | 121 |
| 17 | Genome-Wide Variation of Cytosine Modifications Between European and African Populations and the Implications for Complex Traits | Genetics | 2013 | 117 |
| 18 | Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia | JAMA Oncology | 2018 | 111 |
| 19 | The impact of site-specific digital histology signatures on deep learning model accuracy and bias | Nature Communications | 2021 | 111 |
| 20 | Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study | Blood Advances | 2017 | 103 |
| 21 | Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia | Leukemia | 2016 | 99 |
| 22 | Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma | Journal of Clinical Oncology | 2021 | 94 |
| 23 | Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). | Journal of Clinical Oncology | 2020 | 89 |
| 24 | Epidemiology and Etiology of Non-Hodgkin Lymphoma | Cancer Treatment and Research | 2015 | 88 |
| 25 | PD‐1 regulates extrathymic regulatory T‐cell differentiation | European Journal of Immunology | 2014 | 87 |
| 26 | Mechanisms of Immune Tolerance in Leukemia and Lymphoma | Trends in Immunology | 2017 | 86 |
| 27 | Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia | Cancer Discovery | 2021 | 83 |
| 28 | Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. | Journal of Clinical Oncology | 2019 | 81 |
| 29 | Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study | Leukemia | 2019 | 76 |
| 30 | Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). | Journal of Clinical Oncology | 2019 | 76 |
| 31 | Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice | Blood | 2014 | 75 |
| 32 | A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma | Pediatric Blood and Cancer | 2016 | 66 |
| 33 | Age-related differences in disease characteristics and clinical outcomes in polycythemia vera | Leukemia and Lymphoma | 2013 | 65 |
| 34 | Patient/Family Education for Newly Diagnosed Pediatric Oncology Patients: Consensus Recommendations from a Children’s Oncology Group Expert Panel | Journal of Pediatric Oncology Nursing | 2016 | 64 |
| 35 | Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses | Annals of Oncology | 2019 | 63 |
| 36 | Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer | Journal of Clinical Oncology | 2020 | 60 |
| 37 | Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets | Nature Cancer | 2020 | 58 |
| 38 | Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases | JAMA Oncology | 2021 | 56 |
| 39 | Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results | Nature Medicine | 2022 | 56 |
| 40 | Recognizing familial myeloid leukemia in adults | Therapeutic Advances in Hematology | 2013 | 55 |
| 41 | Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design | Future Oncology | 2019 | 55 |
| 42 | Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia | Biology of Blood and Marrow Transplantation | 2019 | 53 |
| 43 | Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance) | Cancer Epidemiology Biomarkers and Prevention | 2018 | 52 |
| 44 | Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study | British Journal of Haematology | 2018 | 51 |
| 45 | A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study | Journal of Thoracic Oncology | 2022 | 49 |
| 46 | β-catenin regulatesc-MycandCDKN1Aexpression in breast cancer cells | Molecular Carcinogenesis | 2016 | 48 |
| 47 | Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma. | Journal of Clinical Oncology | 2017 | 45 |
| 48 | A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609) | Clinical Cancer Research | 2022 | 45 |
| 49 | IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC). | Journal of Clinical Oncology | 2020 | 43 |
| 50 | Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium | Clinical Genitourinary Cancer | 2019 | 42 |
